Sufentanil modifies the antibacterial activity of bupivacaine and ropivacaine.
OBJECTIVE
The purpose of our study was to investigate the effect on the growth of Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and Enterococcus faecalis (E. faecalis) of bupivacaine at a final concentration of 0.77 mg.mL(-1), ropivacaine at 1.2 mg.mL(-1), and sufentanil at 0.38 and 0.5 microg.mL(-1) (alone or in combination with bupivacaine and ropivacaine).


METHODS
The strains were diluted to approximately 3 x 10(4) cfu.mL(-1) in Mueller-Hinton broth. The anesthetics (0.5 mL) were incubated with the bacterial suspensions (0.5 mL) for 24 hr at 37 degrees C.


RESULTS
Bupivacaine inhibited the growth of E. coli (59 +/- 0.8%; P < 0.05) and S. aureus (22 +/- 3.6%; P < 0.05). Ropivacaine also inhibited the growth of E. coli (41 +/- 1.2%; P < 0.05) and S. aureus (25.5 +/- 4.1%; P < 0.05). Both anesthetics were ineffective against E. faecalis. Sufentanil only inhibited S. aureus (13.8 +/- 3.1%; P < 0.05) at a concentration of 0.5 microg.mL(-1). Sufentanil modified the antibacterial activity of bupivacaine and ropivacaine. It increased the inhibitory effect of bupivacaine on E. faecalis and S. aureus by 10 +/- 2.1% (P < 0.05) and on E. coli by 7% (P < 0.05). Sufentanil did not increase the inhibitory effect of ropivacaine on the growth of S. aureus. On the other hand, sufentanil reduced the inhibitory effect of ropivacaine on E. coli by 11% (P < 0.05).


CONCLUSIONS
Both bupivacaine and ropivacaine alone or combined with sufentanil inhibited the growth of E. coli and S. aureus. E. faecalis was partially sensitive to a bupivacaine + sufentanil mixture. Sufentanil had a partial synergistic effect on bupivacaine and a partial antagonistic effect on ropivacaine's antibacterial activity.
Tamanai-Shacoori
Zohreh
Z
Laboratoire de Micbiologie Pharmaceutique, 1254 Faculté de Pharmacie 2 Av. du Pr Léon Bernard, 35043 Rennes Cedex, France. zohreh.shacoori@univ-rennes1.fr
Shacoori
Valliollah
V
Vo Van
Jean-Marie
JM
Robert
Jean-Claude
JC
Bonnaure-Mallet
Martine
M
D000577:Amides / Q000494:pharmacology*; D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D000779:Anesthetics, Local / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002045:Bupivacaine / Q000494:pharmacology*; D004336:Drug Antagonism; D004357:Drug Synergism; D013293:Enterococcus faecalis / Q000187:drug effects / Q000254:growth & development; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D006801:Humans; D000077212:Ropivacaine; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D017409:Sufentanil / Q000494:pharmacology*
D000577:Amides; D018686:Anesthetics, Intravenous; D000779:Anesthetics, Local; D000900:Anti-Bacterial Agents; D000077212:Ropivacaine; D017409:Sufentanil; D002045:Bupivacaine